CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients
Stopped scarce enrolment and presentation of positive results of similar study in June 2012.
Conditions
- Non-Small Cell Lung Cancer
Interventions
- DRUG: gemcitabine
- DRUG: cisplatin
Sponsor
National Cancer Institute, Naples
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]